Molecular profiles of finasteride effects on prostate carcinogenesis

Cancer Prevention Research

Volumn 2, Issue 6, 2009, Pages 518-524

  Li, Jin ^a   Kim, Jeri ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PLACEBO; ANDROGEN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; AZASTEROID; ISOENZYME; STEROID 5ALPHA REDUCTASE; TUMOR PROTEIN;

APOPTOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CLINICAL TRIAL; DRUG EFFECT; EPITHELIUM CELL; HUMAN; IMPOTENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SHORT SURVEY; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL; ADENOCARCINOMA; ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PATIENT SELECTION; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZASTEROIDS; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; EPITHELIAL CELLS; FINASTERIDE; HUMANS; ISOENZYMES; MALE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STROMAL CELLS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 68949170693     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0241     Document Type: Short Survey

References (59)

1. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224
2. Andriole GL, Pettaway CA, Teloken C, Fowler IL, Somerville MC. Incidence of biopsy-detectable prostate cancer in the REduction of DUtasteride of Prostate Cancer Events (REDUCE) trial: blinded 2-year results [abstract 2207]. Presented at the Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, Illinois.
3. Andriole G, Bostwick D, Brawley O, et al. Further analysis from the REDUCE Prostate Cancer Risk Reduction Trial [abstract LBA1]. Presented at the Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, Illinois.
4. Gomella LG, Tindall DJ, Rittmaster RS, Wilson TH. Influence of baseline patient characteristics on the incidence of high-grade (Gleason score >7) biopsydetectable prostate cancer events in the REduction of DUtasteride of Prostate Cancer Events (REDUCE) trial [abstract 2208]. Presented at the Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, Illinois.
5. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-1317 (Pubitemid 39249705)
6. National Comprehensive Cancer Network. Guidelines for treatment of cancer by site. Fort Washington (PA): National Comprehensive Cancer Network; 2007. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines. asp.
7. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res 2008;1:182-186
8. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-181
9. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552-562 (Pubitemid 18060946)
10. Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C. Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol Int 1998;60:25-9, 30.
11. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753 (Pubitemid 20194126)
12. Rittmaster RS. Finasteride. N Engl J Med 1994;330:120-125
13. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-1191
14. Laroque PA, Prahalada S, Molon-Noblot S, et al. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-α reductase inhibitors. Prostate 1995;27:121-128
15. Stoner E. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992;147:1298-1302
16. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81:814-819
17. Sutton MT, Yingling M, Vyas A, et al. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate 2006;66:1194-1202
18. Bozec A, Ruffion A, Decaussin M, et al. Activation of caspases-3,-6, and -9 during finasteride treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 2005;90:17-25.
19. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-919
20. Iczkowski KA, Qiu J, Qian J, et al. The dual 5-α-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005;65:76-82.
21. Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007;28:763-769
22. Uemura M, Tamura K, Chung S, et al. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-86
23. Li J, Mills GB, Huang M, Lin SH, Logothetis CJ, Kim J. Differential and cell type-dependent transcriptional regulation of SRD5A1, SRD5A2, and SRD5A3 in the androgen receptor pathway in prostate cancer. Philadelphia (PA): American Association for Cancer Research; 2009, Abstract 935.
24. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-5463
25. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-6845
26. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261
27. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-1671
28. Koivisto PA, Schleutker J, Helin H, Ehren-van Eekelen C, Kallioniemi OP, Trapman J. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 1999;5:3578-3582
29. Elo JP, Kvist L, Leinonen K, et al. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 1995;80:3494-3500
30. Castro-Magana M, Angulo M, Fuentes B, et al. Effect of finasteride on human testicular steroidogenesis. J Androl 1996;17:516-521
31. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951
32. Sharifi N, Hurt EM, Farrar WL. Androgen receptor expression in prostate cancer stem cells: is there a conundrum? Cancer Chemother Pharmacol 2008;62:921-923
33. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
34. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001;10:237-242
35. Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998;78:1296-1300
36. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003;31:169-183
37. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241
38. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321
39. Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999;107:49-57.
40. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576
41. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-24505
42. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000;86:855-862
43. Drew L, Fine RL, Raffo AJ, Petrylak DP. Sustained activation of extracellular signal kinase (ERK) signaling in human prostate cancer LNCaP cells depleted of androgen. Prostate J 2001;3:105-117
44. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 1996;93:11802-11807
45. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072-4079
46. Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 2007;31:36-100.
47. Scheel C, Onder T, Karnoub A, Weinberg RA. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007;67:11476-11480
48. Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006;33:201-210
49. Avila DM, Fuqua SA, George FW, McPhaul MJ. Identification of genes expressed in the rat prostate that are modulated differently by castration and finasteride treatment. J Endocrinol 1998;159:403-411
50. Cayatte C, Pons C, Guigonis JM, et al. Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein. Mol Cell Proteomics 2006;5:2031-2043
51. Bass R, Perry B, Langenstroer P, et al. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol 2009;181:615-620
52. Subramaniam DS, Isaacs C. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 2005;6:147-159
53. Ciocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;13:1-10.
54. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009;27:1502-1516
55. Kramer BS, Hagerty KL, Justman S, et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009;181:1642-1657
56. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-1383
57. Tsavachidou D, McDonnell TJ, Wen S, et al. Selenium and vitamin E: cell type- and interventionspecific tissue effects in prostate cancer. J Natl Cancer Inst 2009;101:306-320
58. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5á-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674-1685
59. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.